Roche für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 851311 / ISIN: CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV		Knock-Outs
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime
Kurs + Chart
Chart (groß)
Times + Sales
Chartvergleich
Börsenplätze
Realtime Push
Orderbuch
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Aktion
Portfolio
Watchlist

Nachrichten zu Roche Holding AG (Inhaberaktie)

02:00		Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer (Roche Holding AG)
10.09.26		U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments (Roche Holding AG)
28.08.26		Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD) (Roche Holding AG)
20.08.26		Roche’s US subsidiary Genentech announces manufacturing expansion in the United States (Roche Holding AG)
24.07.26		CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD) (Roche Holding AG)
15.07.26		FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy (Roche Holding AG)
14.07.26		Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis (Roche Holding AG)
09.07.26		Roche receives CE Mark for blood test to identify tuberculosis infection (Roche Holding AG)
07.07.26		Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC (Roche Holding AG)
02.07.26		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer (Roche Holding AG)
30.06.26		FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) (Roche Holding AG)
29.06.26		Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform (Roche Holding AG)
18.06.26		FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma (Roche Holding AG)
12.06.26		Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer (Roche Holding AG)
11.06.26		FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer (Roche Holding AG)
08.06.26		Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology (Roche Holding AG)
02.06.26		FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting (Roche Holding AG)
01.06.26		Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions (Roche Holding AG)
27.05.26		Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management (Roche Holding AG)
19.05.26		Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer (Roche Holding AG)
12.05.26		Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (Roche Holding AG)
07.05.26		Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics (Roche Holding AG)
30.04.26		Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 (Roche Holding AG)
21.04.26		Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD (Roche Holding AG)
21.04.26		FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus (Roche Holding AG)
13.04.26		Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis (Roche Holding AG)
30.03.26		Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply (Roche Holding AG)
23.03.26		Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development (Roche Holding AG)
16.03.26		Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions (Roche Holding AG)
10.03.26		Roche Annual General Meeting 2026 (Roche Holding AG)
09.03.26		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer (Roche Holding AG)
06.03.26		New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus (Roche Holding AG)
05.03.26		Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity (Roche Holding AG)
20.02.26		FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer (Roche Holding AG)
17.02.26		Change to the Roche Enlarged Corporate Executive Committee (Roche Holding AG)
16.02.26		Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease (Roche Holding AG)
07.02.26		Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS) (Roche Holding AG)
29.01.26		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth (Roche Holding AG)
27.01.26		[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity (Roche Holding AG)
22.12.25		FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma (Roche Holding AG)
11.12.25		Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu (Roche Holding AG)
10.12.25		Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer (Roche Holding AG)
09.12.25		Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark (Roche Holding AG)
09.12.25		European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis (Roche Holding AG)
08.12.25		Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas (Roche Holding AG)
08.12.25		Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study (Roche Holding AG)
02.12.25		Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis) (Roche Holding AG)
19.11.25		European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma (Roche Holding AG)
18.11.25		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer (Roche Holding AG)
03.11.25		Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus (Roche Holding AG)

1 | Weiter

Newssuche

Roche Peer Group Nachrichten

11.09.26		QIAGEN-Analyse: Hold-Bewertung von Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) für Aktie
11.09.26		DAX 40-Titel Bayer-Aktie: So viel hätte eine Investition in Bayer von vor 5 Jahren abgeworfen
10.09.26		Bayer-Aktie im Minus: US-Gesundheitsbehörde billigt Sevabertinib bei Lungenkrebs
10.09.26		Analyse: Deutsche Bank AG bewertet Bayer-Aktie mit Buy in neuer Analyse
09.09.26		Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Gewinn hätte ein Investment in Johnson Johnson von vor 5 Jahren eingefahren
09.09.26		Analyse: JP Morgan Chase & Co. bewertet Fresenius SE-Aktie mit Overweight in neuer Analyse
08.09.26		Sanofi-Aktie dennoch im Minus: EU-Freigabe für Millionenförderung einer neuen Insulinfabrik erhalten
08.09.26		Novartis-Aktie deutlich leichter: Neuromuskulärer Wirkstoff verfehlt Ziel in Phase-III-Studie

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	13.09.2026 06:29
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie

WKN: 851311 / ISIN: CH0012032113

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten